• FirefoxUpgrade to the new Firefox »
  •  Dow Up 1.31% Nasdaq Up 0.98%

    More On RNUGF

    Quotes

    Charts

    News & Info

    Company

    Analyst Coverage

    • Analyst Opinion
    • Analyst Estimates

    Ownership

    • Major Holders
    • Insider Transactions
    • Insider Roster

    Financials

    • Income Statement
    • Balance Sheet
    • Cash Flow

    ReNeuron Group plc (RNUGF)

    -Other OTC
    0.02 Down 0.03(56.52%) Jan 29, 2:09PM EST
    Add to Portfolio
    Prev Close:0.05
    Open:N/A
    Bid:N/A
    Ask:N/A
    1y Target Est:N/A
    Beta:N/A
    Next Earnings Date:N/A
    Day's Range:N/A - N/A
    52wk Range:0.02 - 0.08
    Volume:0
    Avg Vol (3m):565
    Market Cap:35.78M
    P/E (ttm):N/A
    EPS (ttm):-0.01
    Div & Yield:N/A (N/A)
    Quotes delayed, except where indicated otherwise. Currency in USD.

    Headlines

    • No Headlines available for RNUGF at this time.

    Key Statistics

    Forward P/E (1 yr):N/A
    P/S (ttm):76.88
    Ex-Dividend Date:N/A

    Analysts

    Annual EPS Est () :N/A
    Quarterly EPS Est () :N/A
    Mean Recommendation*:N/A
    PEG Ratio (5 yr expected):N/A

    * (Strong Buy) 1.0 - 5.0 (Sell)

    Analyst Opinion | Estimates

    Business Summary

    ReNeuron Group plc is engaged in the research and development of stem cell technologies for therapeutic and non-therapeutic applications worldwide. Its lead therapeutic candidate is ReN001 stem cell therapy, which is in Phase II clinical trial for... View More
    Your browser doesn't support canvas
    SETTINGS
    Scrolling
    Speed
    Display
    Price
    Submit Feedback